Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.47 |
| ▸ | ESR1 | P03372 | 12/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333989 | 0.80 | ESR1 (0.51) | ESR1ESR2 | |
| SCHEMBL2336235 | 0.70 | ACP1 (0.60) | PTPN1ESR1PIM1ESR2ACP1 | |
| SCHEMBL2130368 | 0.66 | CA2 (0.73) | ESR1PIM1ESR2 | |
| SCHEMBL15003270 | 0.66 | MAOA (0.49) | ESR1ESR2 | |
| SCHEMBL2332295 | 0.65 | ALDH1A1 (0.76) | ESR1ESR2 | |
| SCHEMBL2334656 | 0.65 | ESR1 (0.77) | ESR1ESR2 | |
| SCHEMBL28456554 | 0.65 | TTR (0.49) | PTPN1 | |
| SCHEMBL7801710 | 0.65 | PTPN1 (1.00) | PTPN1 | |
| SCHEMBL14157073 | 0.65 | APP (0.68) | — | |
| SCHEMBL1289403 | 0.64 | CA12 (0.70) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | claimed |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-02-18 | — | — | US | claimed |
| EP-2533638-B1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | NIVALIS THERAPEUTICS INC (US) | 2016-02-10 | — | — | EP | claimed |
| US-20140275185-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-8759548-B2 | S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | claimed |
| CN-102869255-A | Novel S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS LLC | 2013-01-09 | — | — | CN | claimed |
| EP-2533638-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | claimed |
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | claimed |
| WO-2011100433-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | claimed |
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-02-18 | — | — | US | disclosed |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-02-18 | — | — | US | disclosed |
| EP-2533638-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2011100433-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011100433-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | PTPN1 2122/4885ESR1 1525/4885PIM1 4230/4885 |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | PTPN1 2122/4885ESR1 1525/4885PIM1 4230/4885 |
| US-20140275185-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | PTPN1 2122/4885ESR1 1525/4885PIM1 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.